Abstract
Until recently, most research efforts aimed at developing anti-cancer tools were focusing on small molecules. Alternative compounds are now being increasingly assessed for their potential anti-cancer properties, including peptides and their derivatives. One earlier limitation to the use of peptides was their limited capacity to cross membranes but this limitation was alleviated with the characterization of cell-permeable sequences. Additionally, means are designed to target peptides to malignant cells. Most anti-cancer peptidic compounds induce apoptosis of tumor cells by modulating the activity of Bcl-2 family members that control the release of death factors from the mitochondria or by inhibiting negative regulators of caspases, the proteases that mediate the apoptotic response in cells. Some of these peptides have been shown to inhibit the growth of tumors in mouse models. Hopefully, pro-apoptotic anti-tumor peptides will soon be tested for their efficacy in patients with cancers.
Keywords: Apoptosis, Bcl-2, cancer, cell-permeable peptides, IAPs, peptides, RasGAP, Smac, anti-cancer tools, cell-permeable sequences, release of death factors, mitochondria, caspases, efficacy
Current Pharmaceutical Biotechnology
Title: Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Volume: 12 Issue: 8
Author(s): David Barras and Christian Widmann
Affiliation:
Keywords: Apoptosis, Bcl-2, cancer, cell-permeable peptides, IAPs, peptides, RasGAP, Smac, anti-cancer tools, cell-permeable sequences, release of death factors, mitochondria, caspases, efficacy
Abstract: Until recently, most research efforts aimed at developing anti-cancer tools were focusing on small molecules. Alternative compounds are now being increasingly assessed for their potential anti-cancer properties, including peptides and their derivatives. One earlier limitation to the use of peptides was their limited capacity to cross membranes but this limitation was alleviated with the characterization of cell-permeable sequences. Additionally, means are designed to target peptides to malignant cells. Most anti-cancer peptidic compounds induce apoptosis of tumor cells by modulating the activity of Bcl-2 family members that control the release of death factors from the mitochondria or by inhibiting negative regulators of caspases, the proteases that mediate the apoptotic response in cells. Some of these peptides have been shown to inhibit the growth of tumors in mouse models. Hopefully, pro-apoptotic anti-tumor peptides will soon be tested for their efficacy in patients with cancers.
Export Options
About this article
Cite this article as:
Barras David and Widmann Christian, Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics, Current Pharmaceutical Biotechnology 2011; 12 (8) . https://dx.doi.org/10.2174/138920111796117337
DOI https://dx.doi.org/10.2174/138920111796117337 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
Current Drug Metabolism From Bone Marrow to Cardiac Atrial Appendage Stem Cells for Cardiac Repair: A Review
Current Medicinal Chemistry Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Current Vascular Pharmacology Management of Ovarian Cancer in Elderly
Reviews on Recent Clinical Trials Is There an Association between Periodontitis and Hypertension?
Current Cardiology Reviews Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease
Current Pharmaceutical Design Itraconazole Induced Congestive Heart Failure, A Case Study
Current Drug Safety Human Embryonic and Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery: Patents and Patented Uses
Recent Patents on Cardiovascular Drug Discovery Fish Oil Supplementation: A Matter of DHA Enzymatic/Non-Enzymatic Oxidation Balance?
Current Nutrition & Food Science Newly Diagnosed Dementia and Increased Risk of Hemorrhagic Stroke: A Nationwide Population-based Study
Current Alzheimer Research Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Antithrombotic Therapy After TAVR
Current Vascular Pharmacology Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design Estrogen Receptor Polymorphisms: Significance to Human Physiology, Disease and Therapy
Recent Patents on DNA & Gene Sequences Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems
Current Pharmaceutical Design Is Targeting microRNAs the Philosopher’s Stone for Vascular Disease?
Current Vascular Pharmacology The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews The Role of the Chemokines in Myocardial Ischemia and Reperfusion
Current Vascular Pharmacology